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Administration of a P2Y12-inhibitor is rec-
ommended by current guidelines in pa-
tients with acute coronary syndromes 
(ACS) (1). In clinical routine, this recom-
mendation often results in pre-treatment 
with the respective P2Y12-inhibitor before 
the coronary anatomy is known. Two ran-
domised trials from the clopidogrel era 
suggested that a significant reduction may 
be achieved with clopidogrel pre-treatment 
regarding the risk of major adverse cardiac 
events, also reflecting the circumstance 
that clopidogrel is a pro-drug with a de-
layed onset of action (2, 3). However, these 
studies were often criticised due to their in-
appropriate designs, long pre-treatment in-
tervals before PCI and lower than recently 
recommended dosage of clopidogrel load-
ing (4). Observational studies also sug-
gested that ST-segment elevation patients 
without clopidogrel pre-treatment had an 
elevated risk for mortality (5) and there-
fore, pre-treatment with clopidogrel be-
came a widely applied strategy in Europe.
However, an important limitation of 
clopidogrel is the high variability of its anti-
platelet efficacy with the consequent result 
of high on-treatment platelet reactivity that 
is associated with an elevated risk for stent 
thrombosis and mortality (6). Indeed, high 
on-treatment platelet reactivity has been 
much discussed and debated, with regards 
to its definition, measurement and useful-
ness to clinical practice (7–9).
The novel oral P2Y12-inhibitors prasu-
grel and ticagrelor provide faster and more 
predictable platelet inhibition as compared 
to clopidogrel, and according to the results 
of two pivotal, large randomised trials, 
these properties resulted in significant re-
ductions in the composite endpoint of car-
diovascular mortality, myocardial infarc-
tion or stroke in patients with ACS (10, 11). 
Since the time needed to achieve peak level 
of P2Y12-inihibition with prasugrel and ti-
cagrelor is substantially shorter than it is 
the case for clopidogrel, it is a relevant 
clinical question whether these novel 
agents should also be used at first medical 
contact or can be postponed until coronary 
anatomy is known and the decision of PCI 
is established (4).
The Comparison of Prasugrel at the 
Time of Percutaneous Coronary Interven-
tion (PCI) or as Pre-treatment at the Time 
of Diagnosis in Patients with Non-ST Elev-
ation Myocardial Infarction (ACCOAST) 
trial was the first randomized trial to assess 
the safety and efficacy of prasugrel pre-
treatment in non-ST elevation acute coron-
ary syndrome (NSTE-ACS) patients (12). 
According to the results, no benefit was 
seen in the composite ischaemic endpoint 
of death from cardiovascular causes, myo-
cardial infarction, stroke, urgent revascu-
larisation, or glycoprotein IIb/IIIa inhibitor 
rescue therapy; however, the pre-treatment 
arm using a halved loading dose of 30 mg 
prasugrel showed a significant excess in 
major bleeding events (hazard ratio [HR]: 
1.90, 95 % confidence interval [CI]: 
1.19–3.02, p=0.006). (12) These results 
made current guidelines prohibit the use of 
prasugrel before coronary angiography in 
patients with NSTE-ACS. (1)
Following this, the Administration of 
Ticagrelor in the Cath Lab or in the Ambu-
lance for New ST-Elevation Myocardial In-
farction to Open the Coronary Artery (AT-
LANTIC) trial aimed at comparing pre- vs 
intrahospital ticagrelor administration in 
patients with ST-segment elevation myo-
cardial infarction (13). As a result, no dif-
ference was observed in the co-primary 
surrogate endpoints between the two study 
arms, and the combined ischaemic second-
ary endpoint showed no difference, either. 
Notably, the investigators observed a sig-
nificant reduction in acute and early defi-
nite stent thrombosis with pre-hospital ti-
cagrelor administration; on the contrary, 
this benefit did not come along with a re-
duction in all-cause mortality. Interestingly, 
an even numerically higher risk for mortal-
ity was found in the group of patients with 
pre-hospital ticagrelor administration 
(3.3 % vs 2.0 %, p=0.08) (13).
These debatable results prompted Dr. 
Serebruany and colleagues to write a criti-
cal viewpoint on the interpretation of the 
results and the implications of the ATLAN-
TIC trial (14). This follows other similar 
provocative critiques of the novel oral 
P2Y12-inhibitors, their trials and the rec-
ommendations for their use in guidelines 
by Serebruany (15, 16).
First, the authors highlight that lack of 
benefit in the surrogate co-primary end-
points of ATLANTIC trial “corresponds 
well” with the PLATO angiographic sub-
study and with lack of early benefit of ti-
cagrelor compared to clopidogrel in the 
PLATO study (10, 13). It should be clearly 
emphasised, however, that any compari-
sons in outcome measures between AT-
LANTIC and PLATO or its substudies are 
of limited value, since PLATO evaluated 
the impact of ticagrelor as reference to 
clopidogrel, while ATLANTIC was a tim-
ing trial, with the single investigational 
agent of ticagrelor (10, 13). Similarly, re-
gional differences in the observed benefit 
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with ticagrelor in contrast to clopidogrel, 
also known as the “North-American para-
dox”, cannot be supported by the results of 
the ATLANTIC trial, because the reference 
arms were completely different. Any unre-
solved issues from the PLATO study re-
garding the relative efficacy and safety of 
ticagrelor in contrast to clopidogrel may 
potentially be answered and evaluated in 
context to the upcoming trials of the huge 
PARTHENON clinical trial program, in-
volving nearly 80,000 patients at high risk 
of cardiovascular events due to their 
underlying disease. Since PLATO, PHILO 
is the only completed randomised, clopido-
grel-controlled trial with ticagrelor. 
 Although the results were not yet pub-
lished, they are presented at www.clinical
trials.gov., also cited by Dr. Serebruany. 
 Although PHILO enrolled a substantially 
lower number of patients (n=800) that may 
result in lack of power to compare hard 
clinical outcomes such as mortality, results 
presented at the www.clinicaltrials.gov 
website suggest no benefit of ticagrelor 
over clopidogrel in East-Asians with ACS. 
(NCT01294462) However, we should wait 
for the peer-reviewed publication to draw 
any meaningful conclusions regarding the 
concerns raised by Dr. Serebruany and 
 colleagues, currently being not more than 
suspicions (14).
Finally, one important aspect needs to 
be highlighted from ATLANTIC trial that 
is also stressed in the Viewpoint article: 
despite the observed reductions in acute 
and early stent thrombosis, all-cause mor-
tality with pre-hospital ticagrelor was going 
in the opposite direction, with a trend to-
wards a worse outcome in the pre-treat-
ment arm at 30 days (odds ratio [OR]: 1.68 
95 % CI: 0.94–3.01, p=0.08), and even 
showing a post-hoc calculated significant p 
value (OR: 3.18 95 % CI: 1.02–9.90, p=0.04) 
for events within 24 hours (h) (13, 14). Im-
portantly, ATLANTIC was not powered for 
30-day mortality or ST, even not for events 
within 24 h, so there is a reasonable prob-
ability that any differences for ST and mor-
tality may be chanceful findings rather 
than true clinical observations. However, 
when putting the study in context, AT-
LANTIC is not the only recent trial that 
leaves us surprised with a complete discon-
nect between stent thrombosis and mortal-
ity. Although the explanations of Dr. Sere-
bruany i. e. stent thrombosis would be a 
universal tool in recent clinical trials “to 
please the sponsor”, is far too provocative 
and should be rejected, our long-lasted 
paradigm associating stent thrombosis re-
ductions with mortality benefit may truly 
be challenged in recent P2Y12-inhibitor 
studies (14). For example, the recently pub-
lished large Dual Antiplatelet Therapy 
(DAPT) trial also showed that a prolonged 
exposure to P2Y12-inhibitors effectively re-
duced stent thrombosis and myocardial in-
farction; however, despite this clear finding, 
a trend towards an excess risk for all-cause 
mortality was found (HR: 1.36, 95 % CI: 
1.00–1.85, p=0.05). (18)
These lines of evidence may suggest that 
in contrast to our prior knowledge, the 
road to an improved survival in modern 
interventional cardiology using new-gener-
ation drug-eluting stents and detailed in-
tracoronary imaging modalities is not 
simply paved with reductions in stent 
thrombosis: as a potential consequence of 
the large reductions in the absolute risk of 
stent thrombosis, stent thrombosis may not 
be the dominant mechanism behind over-
all mortality any more, and other factors 
such as bleeding, arrhythmias and non-car-
diac events might have an enlarged impact 
in overall patient survival.
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